Key result
Transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis across the surgical risk spectrum, with ongoing trials exploring new indications.
TAVR is an established treatment across the surgical risk spectrum for aortic stenosis, with ongoing trials exploring new indications such as asymptomatic severe AS and moderate AS with reduced LV function.
Extends TAVR evaluation to asymptomatic severe and moderate AS with reduced LV function; leaves open whether early intervention improves outcomes.
Transcatheter aortic valve replacement (TAVR) has become a valuable treatment option for all patients requiring a bioprosthesis for aortic stenosis (AS). Since its first adoption in 2002, several trials have shown feasibility throughout the entire surgical risk spectrum.1–7 Trials that are currently ongoing explore new indications. An early TAVR strategy in asymptomatic patients with severe AS (NCT03042104) or TAVR in patients with moderate AS and reduced LV function (NCT02661451) might further alter current practice and set the stage for TAVR.
No takes yet. Share an insight, caveat, or question.
Wiechen et al. (2020) conducted a review in Aortic stenosis. Transcatheter aortic valve replacement (TAVR) was evaluated. Transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis across the surgical risk spectrum, with ongoing trials exploring new indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: